Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery: A randomised, double-blind study

被引：68

作者：

Jungheinrich C. ^{[1
]}

Sauermann W. ^{[2
]}

Bepperling F. ^{[1
]}

Vogt N.H. ^{[3
]}

机构：

[1] Clinical Research, D-61346 Bad Homburg, Fresenius Kabi

[2] DATAMAP GmbH Biostatistics Inst., Freiburg

[3] Department of Anaesthesiology, St Hedwig Hospital, Berlin

来源：

Drugs in R & D | 2004年 / 5卷 / 1期

关键词：

Factor VIII; Hydroxyethyl Starch; Colloid Osmotic Pressure; Vecuronium Bromide; Coagulation Factor VIII;

D O I：

10.2165/00126839-200405010-00001

中图分类号：

学科分类号：

摘要：

Background and objective: Different types of hydroxyethyl starch (HES) affect blood coagulation differently. We studied the effects of HES 130/0.4 on coagulation in major orthopaedic surgery in relation to the pharmacological parameter in vivo molecular weight. Methods: 52 patients were randomly allocated to either HES 130/0.4 (6%, mean molecular weight 130 kDa, molar substitution 0.4) or HES 200/0.5 (6%, control) in a double-blind fashion. Colloidal volume requirements for intra- and postoperative haemodynamic stabilisation were compared. Safety analyses of this pharmacological study included a comparison of coagulation factor tests, in vivo molecular weight, and HES plasma concentrations. Results: The colloidal volumes given were similar at the end of surgery (1602 ± 569 for HES 130/0.4 vs 1635 ± 567mL for HES 200/0.5), 5h later (1958 ± 467 vs 1962 ± 398mL), and up to the first postoperative day (2035 ± 446 vs 2000 ± 424mL). HES in vivo molecular weight at the end of surgery was 88 707 ± 13 938 versus 158 374 ± 33 933Da (p < 0.001) and 5h later was 86 663 ± 16 126 versus 136 299 ± 26 208Da (p < 0.001). In parallel to the lower in vivo molecular weight, factor VIII and von Willebrand factor returned to almost normal in the HES 130/0.4 group up to 5h postoperatively, but not in the control group (p < 0.05). Residual HES plasma concentrations after 24h were low in the HES 130/0.4 group (1.0 mg/mL), but higher in the control group (2.6 mg/mL). Conclusion: HES 130/0.4 and HES 200/0.5 were found to be similar with regard to volume efficacy. Sensitive coagulation parameters returned more rapidly to normal in the HES 130/0.4 group. Lower in vivo molecular weight and more rapid excretion of HES 130/0.4 are the likely explanations for the smaller influence on coagulation in this group.

引用

页码：1 / 9

页数：8

共 21 条

[11]

Kasper S.M., Meinert P., Kampe S., Et al., Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses, Anesthesiology, 99, pp. 42-47, (2003)

[12]

Ellger B., Freyhoff J., van Aken H., Et al., High dose volume replacement using HES 130/0.4 during major surgery does not alter coagulation, Eur. J. Anaesthesiol., 19 SUPPL. 24, (2002)

[13]

Neff T.A., Doelberg M., Jungheinrich C., Et al., Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury, Anesth. Analg., 96, pp. 1453-1459, (2003)

[14]

Waitzinger J., Bepperling F., Pabst G., Et al., Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification (HES 130/0.4) after single-dose infusion of 6% or 10% solutions to healthy volunteers, Clin. Drug Invest., 16, pp. 151-160, (1998)

[15]

Jungheinrich C., Scharpf R., Wargenau M., Et al., The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 ml) in mild-to-severe renal impairment, Anesth. Analg., 95, pp. 544-551, (2002)

[16]

Mishler J.M., Durr G.H., Macroamylasemia induced by hydroxyethyl starch: Confirmation by gel filtration analysis of serum and urine, Am. J. Clin. Pathol., 74, pp. 387-391, (1980)

[17]

Waitzinger J., Bepperling F., Pabst G., Et al., Effect of a new HES specification (6% HES 130/0.4) on blood and plasma volume after bleeding in 12 healthy male volunteers, Clin. Drug Invest., 17, pp. 119-125, (1999)

[18]

Ruttmann T.G., James M.F., Aronson I., In vivo investigation into the effects of haemodilution with hydroxyethyl starch (200/0.5) and normal saline on coagulation, Br. J. Anaesth., 80, pp. 612-616, (1998)

[19]

Konrad C.J., Markl T.J., Schuepfer G.K., Et al., In vitro effects of different medium molecular hydroxyethyl starch solutions and lactated Ringer's solution on coagulation using SONOCLOT, Anesth. Analg., 90, pp. 274-279, (2000)

[20]

Entholzner E.K., Mielke L.L., Calatzis A.N., Et al., Coagulation effects of a recently developed hydroxyethyl starch (HES 130/0.4) compared to hydroxyethyl starches with higher molecular weight, Acta Anaesthesiol. Scand., 44, pp. 1116-1121, (2000)

← 1 2 3 →